Expertise in action. Leadership with vision
Our Senior Leadership Team
Our leadership team brings together specialized scientific insight, clinical excellence, and strategic business acumen. With a global outlook and a bold commitment to patient-centered progress, this team guides Corbus with precision and agility, advancing high-potential therapies through critical stages of development and delivering measurable impact for patients and the company’s growth.
By consistently emphasizing our vision, mission, and core values in every decision, they lead by example in upholding the highest standards of integrity and excellence. Their collaborative approach and proven regulatory expertise ensure that progress is matched by execution, moving our work forward with confidence and clarity.
Yuval Cohen, Ph.D.
Yuval Cohen, Ph.D., Chief Executive Officer and Director
Dr. Cohen has served as our Chief Executive Officer and as a director since April 11, 2014. Prior to joining Corbus Pharmaceuticals, Inc., he was the President and co-founder of Celsus Therapeutics PLC (“Celsus”). Dr. Cohen holds a BSc (Hons) in microbiology and biochemistry from University of Cape Town, South Africa, and has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V.
Show more
Dr. Cohen was selected as a director because of his business and leadership experience in the biopharmaceutical sector, as well as a result of his experience serving as our Chief Executive Officer since our inception.
Sean Moran, CPA, MBA
Chief Financial Officer
Mr. Moran has served as our Chief Financial Officer since April 11, 2014. Mr. Moran joined Corbus Pharmaceuticals, Inc. (formerly JB Therapeutics), our wholly-owned subsidiary, as its Chief Financial Officer in January 2014. Mr. Moran has over twenty-five years of senior financial experience with emerging biotechnology, drug delivery and medical device companies. Mr. Moran has worked at three different companies that completed initial public offerings and maintained a listing on a public exchange.
Show more
Before joining our company, Mr. Moran served as Director of Finance and then as Chief Financial Officer for InVivo Therapeutics Corporation from 2010 to 2013 and served as Chief Financial Officer of Celsion Corporation from 2008 to 2010, Transport Pharmaceuticals Inc. from 2006 to 2008, Echo Therapeutics Inc. from 2002 to 2006, SatCon Technology Corporation from 2000 to 2002, and Anika Therapeutics Inc. from 1993 to 2000. Mr. Moran is a CPA by training and earned his M.B.A. and a B.S. in Accounting from Babson College.
Dr. Dominic Smethurst, MA MRCP
Chief Medical Officer
Dr. Smethurst has served as our Chief Medical Officer since February 27, 2024. Before joining our company, Dr. Smethurst served as the Chief Medical Officer of Bicycle Therapeutics PLC (Nasdaq: BCYC), a clinical-stage biopharmaceutical company developing a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom, from August 2020 to October 2023. Prior to his position at Bicycle Therapeutics, from February 2019 to August 2020.
Show more
Dr. Smethurst served as interim Chief Medical Officer for Nordic Nanovector ASA, where he was responsible for design, strategy and implementation of clinical trials for drug development. Dr. Smethurst earned his MA and MBChB degrees in Medicine at Christ's College, Cambridge, UK, and his MRCP degree in Medicine from Queens Medical Center, Nottingham, UK.
Ian Hodgson, BSc (Hons), Ph. D.
Chief Operating Officer
Dr. Ian Hodgson has served as our Chief Operating Officer since March 15th, 2025. Dr. Hodgson has over 25 years of experience in drug development and operations across biotech, large pharmaceutical companies and contract research organizations.
Show more
Dr. Hodgson joined Corbus International Ltd. in October 2022 as Head of Clinical and European Operations and transitioned to Head of Operations in March of 2024. Since May 2021, Dr. Hodgson has served as a non-executive director and board advisor for MD Group Ltd., a privately owned patient services company, and Skyelarke, a health-tech company specializing in delivering patient payments in clinical trials. Previously, he held several leadership positions, including Vice President, Head of Clinical Services at TMC Pharma Services Ltd., a rare disease consultancy from September 2021 through September 2022, Vice President, Clinical Development – Rare Diseases at Syneos Health from November 2020 through September 2021, and Head of Clinical Operations at Mereo Biopharma from 2015 through 2020.
Dr. Hodgson earned a PhD in Medical Microbiology from Queen Margaret University in collaboration with the University of Edinburgh (awarded by the Open University) and a BSc (Hons) in Food Technology from Reading University.
Christina Bertsch. M.A.
VP of Human Resources
Christina Bertsch joined Corbus in April 2020. She has over 25 years of experience in human resources as both a management consultant and as an HR executive, primarily in the life sciences industry. Ms. Bertsch has significant experience in HR strategic planning, mergers & acquisitions, change management, executive coaching & development and building scalable HR infrastructures for growing companies. Her expertise areas span the full employee lifecycle including talent acquisition, workforce development, performance management, succession planning, total rewards as well as employee engagement and retention.
Show more
Ms. Bertsch has been a consultant to a number of organizations within the life sciences space including Stoke Therapeutics, Glycomine, Jounce Therapeutics, Luminopia, Magenta Therapeutics, Ironwood, Bruker, Merus, and Sarepta Therapeutics. Previous to starting her consulting business she was Senior Vice President of Human Resources at Santander Holdings US, Vice President of Human Resources at Beacon Partners and US Business Partner & Director of Talent Management & Development at EMD Serono.
She holds a Bachelor’s Degree from Manhattanville College, and a Master’s Degree in Industrial / Organizational Psychology from Hofstra University.
G. Scott Goeken, M.S., J.D.
General Counsel & Corporate Secretary
Mr. Goeken is the General Counsel and Corporate Secretary at Corbus Pharmaceuticals, Inc., bringing over 20 years of experience at the intersection of law, pharmaceutical research, and regulatory strategy. In his current role, he provides comprehensive legal leadership across a broad spectrum of corporate matters, including regulatory compliance, corporate governance, capital markets, risk management, and strategic advisory to the executive team.
Show more
Previously, Mr. Goeken held senior roles at Corbus, including Vice President, Head of Regulatory Affairs, and Director of Regulatory CMC. He spent 12 years at Pfizer, where he held a variety of technical and regulatory positions in formulation development, materials science, and regulatory affairs.
A respected leader in the pharmaceutical industry, Mr. Goeken has extensive experience in pharmaceutical legal transactions, intellectual property strategy, and the development of regulatory affairs strategies spanning pre-clinical stages through post-approval. Additionally, he brings over 15 years of experience as a technical consultant in global patent litigation and prosecution within the pharmaceutical sector.
Mr. Goeken holds a B.S. in Chemistry with minors in Business and Statistics, an M.S. in Analytical Chemistry from Purdue University, and a J.D. from the University of Connecticut School of Law. He is licensed to practice in Connecticut and Massachusetts.
Our Board of Directors
Our Board of Directors provides strategic guidance to drive Corbus’s growth and success. With diverse expertise in science, business, legal affairs, international trade, and global biopharmaceutical development, the Board helps shape corporate strategy, financial performance, and risk management.
Focused on both commercial success and responsible governance, the Board plays a critical role in supporting Corbus’s mission with clear, forward-thinking leadership.